Rapport Therapeutics, Inc. (Nasdaq: RAPP) announced the pricing of an underwritten public offering of 9,615,385 shares of its common stock at $26.00 per share, expected to raise approximately $250.0 million. The offering is expected to close on September 11, 2025. Goldman Sachs, Jefferies, TD Cowen, and Stifel are acting as joint book-running managers for the offering. Rapport is a biotechnology company focused on small molecule precision medicines for neurological and psychiatric disorders, with a pipeline including RAP-219 for various conditions like drug-resistant seizures and diabetic neuropathic pain.

Investors can access the final prospectus supplement and accompanying prospectus for the offering from participating banks or the SEC website. Rapport Therapeutics’ RAP technology platform targets receptor associated proteins in the brain to create precision small molecule drug candidates. The company’s lead candidate, RAP-219, is being developed for conditions like bipolar mania and chronic pain, with additional programs targeting hearing disorders and more. This press release contains forward-looking statements about the offering, subject to risks and uncertainties outlined in Rapport’s filings with the SEC. Contact Julie DiCarlo, Head of Communications & IR, for more information.

Read more at GlobeNewswire: Rapport Announces Pricing of Public Offering of Common